Barr et al., 2012 - Google Patents
Syk inhibition with fostamatinib leads to transitional B lymphocyte depletionBarr et al., 2012
View PDF- Document ID
- 6202224302947641505
- Author
- Barr P
- Wei C
- Roger J
- Schaefer-Cutillo J
- Kelly J
- Rosenberg A
- Jung J
- Sanz I
- Friedberg J
- Publication year
- Publication venue
- Clinical Immunology
External Links
Snippet
Cell signaling initiated by the B cell receptor is critical to normal development of B lymphocytes, most notably at the transitional B cell stage. Inhibition of this signaling pathway with the syk inhibitor, fostamatinib, has produced significant efficacy in lymphoid …
- 230000002401 inhibitory effect 0 title abstract description 30
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kovtonyuk et al. | IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice | |
Eaves | Hematopoietic stem cells: concepts, definitions, and the new reality | |
Ponzetta et al. | Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors | |
Metcalfe et al. | Pathogenesis and pathology of mastocytosis | |
Arock et al. | Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives | |
Young et al. | Targeting pathological B cell receptor signalling in lymphoid malignancies | |
Knippenberg et al. | Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission | |
Rosenkranz et al. | Zinc supplementation induces regulatory T cells by inhibition of Sirt‐1 deacetylase in mixed lymphocyte cultures | |
Chabbi-Achengli et al. | Decreased osteoclastogenesis in serotonin-deficient mice | |
Martínez-Cué et al. | Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome | |
Mócsai et al. | Syk is required for integrin signaling in neutrophils | |
Ponader et al. | The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | |
Barr et al. | Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion | |
Mongini et al. | TLR-9 and IL-15 synergy promotes the in vitro clonal expansion of chronic lymphocytic leukemia B cells | |
D D'Souza et al. | Reducing mitochondrial ROS improves disease-related pathology in a mouse model of ataxia-telangiectasia | |
de Leseleuc et al. | PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages | |
Herrera et al. | A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease | |
Winer et al. | PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies | |
Burger | Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia | |
EP3433365B1 (en) | T-cell exhaustion state-specific gene expression regulators and uses thereof | |
Yazicioglu et al. | Dynamic mitochondrial transcription and translation in B cells control germinal center entry and lymphomagenesis | |
Mizoguchi et al. | Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib | |
Kurkó et al. | Suppression of proteoglycan-induced autoimmune arthritis by myeloid-derived suppressor cells generated in vitro from murine bone marrow | |
Uehara et al. | Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ | |
Chen et al. | Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases |